How long does Wegovy treatment last — and what happens over time?

How long does the titration phase take before Wegovy is at full strength?

Wegovy does not start at its maintenance dose. The schedule moves up gradually, 0.25mg, then 0.5mg, 1.0mg, 1.7mg and finally 2.4mg, each step held for roughly four weeks. That puts the earliest arrival at the standard maintenance dose at around week 16 to 20. For people now moving toward the 7.2mg dose approved by the MHRA in April 2026, the journey is longer still, since 2.4mg remains the stepping-stone. This pacing exists for a real reason: slower titration reduces the likelihood of nausea and other gastrointestinal side effects that are most noticeable when semaglutide is first introduced or increased. The starter dose is doing a job of acclimatisation, not treatment in the full sense. It is worth knowing this upfront, because many people expect rapid change in the first weeks and feel discouraged when it does not arrive on cue. Weight loss tends to accelerate once the maintenance dose is established and the body has adjusted, and understanding how Wegovy expiration dates work can help you plan your supply across the full titration period without wasting doses.

Your prescriber decides the titration pace. Some people hold at a lower dose for longer if side effects are significant; moving faster is rarely recommended. For a closer look at how the medicine itself is put together, the semaglutide preparation page covers the formulation in more detail.

Does Wegovy have a maximum treatment duration, or can you stay on it indefinitely?

A question our prescribers hear most weeks is whether Wegovy is meant to be a permanent fixture or a temporary fix. The honest answer is: it depends on the clinical setting. On the NHS, NICE TA875 sets a ceiling of two years for semaglutide, specifically because the recommendation is tied to specialist weight management services with multidisciplinary support, and that structured package has a defined scope. In the private-prescription setting, the licence itself does not impose a two-year cap; the medicine is approved for long-term weight management, and the prescriber reviews whether continuing is clinically appropriate at each repeat.

What the trial data does tell us (clearly) is that weight lost on semaglutide tends to return after stopping. The STEP 1 trial, published in the New England Journal of Medicine, found participants regained a significant portion of lost weight within a year of discontinuation. That is not a flaw in the medicine; it reflects the biology of weight regulation, which does not reset simply because a treatment course ends. Duration decisions therefore involve a genuine clinical conversation (not a formulaic cut-off) about your health trajectory, your other conditions, and what stopping would mean practically.

What is the six-month review point, and what triggers a reassessment?

NICE guidance on semaglutide includes a practical checkpoint: if fewer than 5% of starting body weight has been lost after six months at the maintenance dose, continuing treatment should be reviewed. That threshold exists because the trial data shows most people who will respond meaningfully to semaglutide do so within this window. It is not an automatic stop, it is a structured moment for the prescriber to weigh up whether the medicine is doing enough work to justify the risks and costs of continuation.

At nume, every repeat prescription involves a fresh clinical review, not an automatic renewal. That review looks at response, any side effects, changes in health status and whether the dose should be adjusted. If you are curious about what that process involves, the Wegovy medication page explains how treatment is monitored over time. For those thinking about how their general health picture fits the treatment, the weight-loss treatment overview outlines the broader clinical criteria in plain terms.

What happens to weight if Wegovy is stopped, and does that change how long people use it?

The rebound effect after stopping GLP-1 medicines is real and reasonably well documented. Studies consistently show that appetite, and therefore weight, begins to recover within weeks of discontinuation, because the medicine's effect on hunger signalling is pharmacological, not permanent. This does not mean everyone needs to stay on Wegovy forever; some people use it as a bridge while making sustained lifestyle changes, and others maintain progress independently. But it does mean that a planned stopping point should involve a clear conversation with your prescriber about what support comes next.

It also explains why duration is not a simple calendar question. Someone who has lost substantial weight, whose health markers have improved, and who is using the treatment period to build new habits around food and activity is in a different clinical position from someone who has plateaued early. Surgery timelines matter too, if you are planning an operation, there are specific guidance points about pausing semaglutide beforehand, which the Wegovy and operations page covers in full.

For context on how Wegovy sits alongside other semaglutide-based options, the broader semaglutide page covers the licensed landscape, including the distinction between Wegovy and Ozempic (which is licensed for type 2 diabetes, not weight management). And if you want to understand how the private-prescription cost fits into duration planning, the Wegovy cost context page sets out what a typical monthly price actually includes.

If you would like to discuss your own situation (how long you have been on treatment, whether your current dose is right, or whether it makes sense to continue) our prescribers are available seven days a week. Speak to our prescribers through a free consultation, with same-day clinical review if you submit before noon on a working day.